Skip to main content
Fig. 5 | BMC Anesthesiology

Fig. 5

From: Paravertebral dexmedetomidine as an adjuvant to ropivacaine protects against independent lung injury during one-lung ventilation: a preliminary randomized clinical trial

Fig. 5

Results of real-time PCR and western blots. Real-time PCR results of miRNA-210 (a) and western blots of HIF-1α (b and e), Tom20 (c and e), and ISCU2 (D and E). aP<0.05 vs. the C group; bP<0.05 vs. the R group; cP<0.05 vs. the Div group; dP<0.05 vs. the RD0.5 group. C, normal saline; R, ropivacaine; Div, intravenous DEX; RD0.5, 0.5 μg/kg DEX as an adjuvant to ropivacaine TPVB; RD1.0, 1.0 μg/kg DEX as an adjuvant to ropivacaine TPVB; RD2.0, 2.0 μg/kg DEX as an adjuvant to ropivacaine TPVB

Back to article page